Chief Scientific Officer

I am a pharmaceutical scientist with 20+ years of experience in polymer science, pharmaceutical formulation, and advanced drug delivery systems, with a focus on translating formulation and polymer-based technologies into clinically relevant products. I specialize in sustained-release formulations, long-acting injectables, and intranasal delivery platforms. Throughout my career, I have held leadership roles in both academic and industry settings, directing programs from early-stage formulation through preclinical development and commercialization. As co-founder and R&D lead at Varian Pharmed Company, I oversaw the development of long-acting formulations of Triptorelin and Luprorelin, which progressed to market. Next, I was a Senior Research Scientist at Emery Pharma, where I contributed to analytical method development, bioanalysis, and drug formulation strategies. As CSO at EmerRx, I lead research and development efforts to develop a new intranasal naloxone formulation aimed at improving bioavailability and achieving a faster onset of action than existing commercial products.